Law firm investigates Esperion Therapeutics' $3.16/share sale deal for fairness

Monteverde & Associates PC, a class action law firm, has launched an investigation into Esperion Therapeutics, Inc.'s proposed sale to ARCHIMED-managed funds. The deal offers Esperion shareholders $3.16 per share in cash plus potential milestone payments. The investigation aims to determine if the transaction terms are fair to shareholders. Investors holding Esperion stock are encouraged to seek more information or legal advice from the firm at no cost or obligation.